ClinicalTrials.gg
CompletedNCT06075277Updated Sep 22, 2025Results posted

A Study in Healthy Men to Test How Zongertinib is Taken up in the Body When Taken With or Without Food

A Phase 1 interventional study of zongertinib in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The main objective of this trial is to investigate the relative bioavailability of a single dose of BI 1810631 intended commercial formulation (iCF) under fed (Test treatment, T) and fasted (Reference treatment, R) conditions.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  2. Age of 18 to 55 years (inclusive)
  3. (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
  4. Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial

Exclusion criteria

Exclusion Criteria:

  1. Any finding in the medical examination (including Blood pressure (BP), pulse rate (PR) or (ECG)) deviating from normal and assessed as by the investigator
  2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
  3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  7. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  8. History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    BI 1810631 (iCF) fed state (Reference, R) then fasting state (Test, T)

    Period 1: Participants received a single oral dose of 240 milligram (mg) Zongertinib as film coated tablets (4x 60 mg tablet) following a high fat/high calorie meal. Period 2: Participants received a single oral dose of 240 milligram (mg) of Zongertinib as film coated tablets (4x 60 mg tablets) following an overnight fast of at least 10 hours.

    Drug: zongertinib

  • Experimental
    BI 1810631 (iCF) fasting state (Test, T) then fed state (Reference, R)

    Period 1: Participants received a single oral dose of 240 milligram (mg) of Zongertinib as film coated tablets (4x 60 mg tablets) following an overnight fast of at least 10 hours. Period 2: Participants received a single oral dose of 240 milligram (mg) Zongertinib as film coated tablets (4x 60 mg tablet) following a high fat/high calorie meal.

    Drug: zongertinib

Interventions

  • Participants received a single oral dose of 240 mg Zongertinib (4 x 60 mg tablets) in two periods: in Period 1 after an overnight fast of at least 10 hours, and in Period 2 following a high fat/high calorie meal.

    Also known as: BI 1810631, Hernexeos®

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of Zongertinib in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). Geometric least square mean (adjusted geometric mean) and geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. These quantities will then be back-transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.

    Time frame: Within 3 hours before Zongertinib administration, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours following administration.

  2. Maximum Measured Concentration of the Zongertinib in Plasma (Cmax)

    Maximum measured concentration of Zongertinib in plasma (Cmax). Geometric least square mean (adjusted geometric mean) and geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. These quantities will then be back-transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.

    Time frame: Within 3 hours before Zongertinib administration, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours following administration.

Secondary outcomes

  1. Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of Zongertinib in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞). Geometric least square mean (adjusted geometric mean) and geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. These quantities will then be back-transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.

    Time frame: Within 3 hours before Zongertinib administration, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours following administration.

07

Results

Posted Sep 22, 2025

Participant flow

This was an open-label, randomized, two-way crossover design trial. Healthy males received a single oral dose of 240 mg Zongertinib (BI 1810631) in its intended commercial formulation (iCF) following an overnight fast and after a standardized high-calorie, high-fat meal. There was a washout period of 14 days between doses. The primary objective was to evaluate how Zongertinib is absorbed when taken with and without food, to determine differences in its bioavailability between these states.

Period 1
Participant flow — Period 1
MilestoneZongertinib iCF Fasted (Reference (R)) /Zongertinib iCF Fed (Test (T))Zongertinib iCF Fed (Test (T)) / Zongertinib iCF Fasted (Reference (R))
Started88
Completed88
Not completed00
Washout Period
Participant flow — Washout Period
MilestoneZongertinib iCF Fasted (Reference (R)) /Zongertinib iCF Fed (Test (T))Zongertinib iCF Fed (Test (T)) / Zongertinib iCF Fasted (Reference (R))
Started88
Completed88
Not completed00
Period 2
Participant flow — Period 2
MilestoneZongertinib iCF Fasted (Reference (R)) /Zongertinib iCF Fed (Test (T))Zongertinib iCF Fed (Test (T)) / Zongertinib iCF Fasted (Reference (R))
Started88
Completed88
Not completed00

Outcome measures

PrimaryArea Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of Zongertinib in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). Geometric least square mean (adjusted geometric mean) and geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. These quantities will then be back-transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.

Time frame:
Within 3 hours before Zongertinib administration, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours following administration.
Reported as:
Geometric mean · hour*nanomol/Liter (h*nmol/L)
Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hour*nanomol/Liter (h*nmol/L)Zongertinib iCF Fed (Test (T))Zongertinib iCF Fasted (Reference (R))
Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)59457.92 ± NA46951.21 ± NA
Statistical analysis
  • Zongertinib iCF Fed (Test (T)) vs Zongertinib iCF Fasted (Reference (R)) · Ratios of adjusted geometric means [%]: 126.64 · 90% CI 112.09 to 143.08Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 19.8
PrimaryMaximum Measured Concentration of the Zongertinib in Plasma (Cmax)

Maximum measured concentration of Zongertinib in plasma (Cmax). Geometric least square mean (adjusted geometric mean) and geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. These quantities will then be back-transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.

Time frame:
Within 3 hours before Zongertinib administration, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours following administration.
Reported as:
Geometric mean · nanomol/Liter (nmol/L)
Maximum Measured Concentration of the Zongertinib in Plasma (Cmax)
nanomol/Liter (nmol/L)Zongertinib iCF Fed (Test (T))Zongertinib iCF Fasted (Reference (R))
Maximum Measured Concentration of the Zongertinib in Plasma (Cmax)4666.87 ± NA3700.37 ± NA
Statistical analysis
  • Zongertinib iCF Fed (Test (T)) vs Zongertinib iCF Fasted (Reference (R)) · Ratios of adjusted geometric means [%]: 126.12 · 90% CI 106.34 to 149.58Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 27.9.
SecondaryArea Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of Zongertinib in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞). Geometric least square mean (adjusted geometric mean) and geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. These quantities will then be back-transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.

Time frame:
Within 3 hours before Zongertinib administration, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours following administration.
Reported as:
Geometric mean · hour*nanomol/Liter (h*nmol/L)
Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hour*nanomol/Liter (h*nmol/L)Zongertinib iCF Fed (Test (T))Zongertinib iCF Fasted (Reference (R))
Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)59986.25 ± NA47594.57 ± NA
Statistical analysis
  • Zongertinib iCF Fed (Test (T)) vs Zongertinib iCF Fasted (Reference (R)) · Ratios of adjusted geometric means [%]: 126.04 · 90% CI 111.70 to 142.21Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 19.6.

Adverse events

Collected over Serious Adverse Events and other adverse events: From first Zongertnib dose up to 14 days. All-cause mortality: From first trial drug administration up to 22 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zongertinib 240mg iCF Fed (T)0/16 (0%)0/16 (0%)7/16 (43.8%)
Zongertinib 240mg iCF Fast (R)0/16 (0%)0/16 (0%)7/16 (43.8%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventZongertinib 240mg iCF Fed (T)Zongertinib 240mg iCF Fast (R)
HeadacheNervous system disorders2/163/16
NauseaGastrointestinal disorders0/161/16
FatigueGeneral disorders0/161/16
PainGeneral disorders0/161/16
NasopharyngitisInfections and infestations1/160/16
Back painMusculoskeletal and connective tissue disorders1/160/16
MyalgiaMusculoskeletal and connective tissue disorders0/161/16
PresyncopeNervous system disorders0/161/16
CoughRespiratory, thoracic and mediastinal disorders0/161/16
Nasal congestionRespiratory, thoracic and mediastinal disorders1/160/16

Baseline characteristics

Treated set (TS): The treated set includes all subjects who were treated with at least one dose of trial drug.

Age, Continuous
Age, Continuous(years)Zongertinib iCF Fasted (Reference (R)) /Zongertinib iCF Fed (Test (T))Zongertinib iCF Fed (Test (T)) / Zongertinib iCF Fasted (Reference (R))Total
Mean50.0 ± 5.845.9 ± 11.247.9 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Zongertinib iCF Fasted (Reference (R)) /Zongertinib iCF Fed (Test (T))Zongertinib iCF Fed (Test (T)) / Zongertinib iCF Fasted (Reference (R))Total
Female000
Male8816
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zongertinib iCF Fasted (Reference (R)) /Zongertinib iCF Fed (Test (T))Zongertinib iCF Fed (Test (T)) / Zongertinib iCF Fasted (Reference (R))Total
Hispanic or Latino000
Not Hispanic or Latino8816
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Zongertinib iCF Fasted (Reference (R)) /Zongertinib iCF Fed (Test (T))Zongertinib iCF Fed (Test (T)) / Zongertinib iCF Fasted (Reference (R))Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White8816
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • CRS Clinical Research Services Berlin GmbH
    Berlin, 13627, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Jan 2024, 2 months.

Results were first posted in Sep 2025, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2023
First posted
Oct 10, 2023
StartActual
Oct 19, 2023
Primary completionActual
Jan 2, 2024
CompletionActual
Jan 2, 2024
Results first posted
Sep 22, 2025
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06075277
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
Oct 19, 2023
Primary completion
Jan 2, 2024
Completion
Jan 2, 2024
Results posted
Sep 22, 2025
Last update
Sep 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zongertinib

Start the discussion